PAGE 01

JUN 0 8 2006

PTO/SB/21 (09-04) Approved for use through 07/31/2006, OMB 0551-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Inder the Paperwork Reduction Act of 1995, no parsons are regulared to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/812,248 TRANSMITTAL Filing Date March 29, 2004 First Named Inventor **FORM** Alex J. Harvey Art Unit Examiner Name Michael C. Wilson (to be used for all correspondence after initial filing) Attorney Docket Number. AVH027 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC 1 Petition (Appeal Notice, Brief, Reply Brief) Amendment/Reply Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Change of Correspondence Address Affidavits/declaration(s) Other Enclosure(s) (please Identify Terminal Disclaimer below): Extension of Time Request Request for Refund Express Abandonment Request CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Capy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application
Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Signature Printed name Kyle Yesland Date Reg. No. 45526 June 8, 2008 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature

This collection of Information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary deparding upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burdon, should be sent to the Chief Information Officer, U.S. Patont and Trademerk Office, U.S. Department of Commerce, P.O. Box 1450, Alexandris, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

June 8, 2006

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Kys Yesland

Typed or printed name

Appl. No. 10/812,248

Response to Office action mailed May 9, 2006

## RECEIVED CENTRAL FAX CENTER

JUN 0 8 2006

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.

10/812,248

Applicant

Harvey, et al

Filed

March 29, 2004

Title

Transgenesis of Early Embryonic Cells

TC/A.U.

1632

Examiner

Michael C Wilson

Docket No.

AVI-27

Thereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop: Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or facsimile transmitted to the U.S. Patent and Trademark Office on or before:

Date Sune 8, 2006

Name Kyle YESTONE

## RESPONSE TO EXAMINER'S COMMUNICATION OF MAY 9, 2006 AND ELECTION OF CLAIMS

Mail Stop: Amendments

Honorable Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir,

In response to the Examiner's communication of May 9, 2006, please enter the following amendment for the above identified application.

Amendments to the Specification begins on page 2 of this paper.

Amendments to the Claims begin on page 3 of this paper.

Remarks begin on page 6 of this paper.